The U.S. Food and Drug Administration has approved a low-cost generic version of liraglutide, a GLP-1 medication, offering relief to patients with Type 2 diabetes amid ongoing shortages, The Hill reported.
The green light is for patients aged 10 and older. This approval addresses the increasing demand for GLP-1 medications, particularly as brand-name versions like Victoza face widespread shortages.
Liraglutide, commonly prescribed to help control blood sugar levels, has been an essential treatment option for millions. The introduction of a generic version provides a more affordable alternative for patients, many of whom struggle with the financial burden of managing chronic conditions.
“Generic drugs provide additional treatment options which are generally more affordable for patients,” Dr. Iilun Murphy, director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research, said in a statement.
The impact of diabetes is far-reaching. According to White House statistics, more than 38 million Americans, or approximately one in every ten people, live with the disease. Type 2 diabetes, the most common form, affects individuals across various age groups, emphasizing the importance of accessible treatment options.
The FDA’s approval reflects its broader commitment to ensuring that patients have access to safe and effective medications. “Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective, and high-quality generic drug products,” Murphy added.
Despite its benefits, liraglutide is not suitable for everyone. Doctors caution against its use in patients with a family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2, as the medication may lead to complications in these cases.
Additionally, some experts have pointed to the superior efficacy of weekly GLP-1 injections compared to daily ones, a consideration that may influence treatment decisions. A recent CNN report highlighted that weekly formulations have demonstrated stronger outcomes in managing blood sugar levels for some patients.
The approval of generic liraglutide provides a critical option for those in need, offering economic relief and increased availability.
Jim Thomas ✉
Jim Thomas is a writer based in Indiana. He holds a bachelor's degree in Political Science, a law degree from U.I.C. Law School, and has practiced law for more than 20 years.
© 2024 Newsmax. All rights reserved.